Dr. Reddy’s Laboratories Ltd. has launched its generic Semaglutide Injection in Canada, making it among the first to do so following Health Canada's approval on April 28, 2026. This launch marks Canada as the first G7 nation to authorize a generic version of the injection, highlighting the company's commitment to expanding immediate patient access. 

In Canada, Dr. Reddy’s Semaglutide Injection Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada is a once-weekly treatment for adults with type 2 diabetes, acting as an adjunct to diet and exercise to improve glycemic control Dr Reddy's receives Health Canada approval for generic semaglutide injection.

Erez Israeli, Chief Executive Officer, Dr. Reddy’s, said: “We are pleased to launch our generic Semaglutide Injection in Canada, within days of receiving Health Canada approval. The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development. With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients. The Canada launch builds on the momentum of our recent launch in India under the brand name Obeda. As GLP-1 therapies continue to be a key focus area for us, we are actively working to expand access across multiple global markets.”